Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Electric Vehicles for Eco-Accommodating Driving - 2Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- 3Vaccine exemptions for religious or personal beliefs are rising across the U.S.
- 4Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- 5Find the Standards of Viable Refereeing: Settling Debates with Strategy
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- Exploring the Main Year of Life as a parent: Individual Encounters
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- The 25 Most Notable Style Crossroads in History
- 10 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- Amid Iran war, 53 of Israel's future scientists showcase projects in Jerusalem contest
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- Artemis II live updates: NASA's moon mission breaks Apollo record for farthest distance humans have traveled from Earth
- Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
